AusCann : Annual General Meeting - CEO Presentation

onlyuse ersonalASX:

AGM Presentation

November 15, 2021

Layton Mills - CEO

AC8

ersonal use only

|2|

Disclaimer

• This presentation has been prepared by AusCann Group Holdings Ltd ACN 008 095 207 ("Company"). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment matters.
• No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in this presentation.
• This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).
• Neither the Company, nor their respective related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.
• Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of their respective directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company actual future results, performance or achievements to be materially different from those expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company warrants or represents that the actual results, performance or achievements will be as expected, planned or intended.

AusCann Snapshot

ersonal use only

Cannabinoid-based	ü An Australian pioneer developing evidence-based healthcare solutions derived from
healthcare Company	the Cannabis plant for under-served medical needs in humans and companion animals;

1st Australian veterinary ü Commenced 1st registration with the APVMA for a patented first-in-class cannabinoid

registration commenced veterinary medicine for skin and immune health in dogs; Market size of over $1B1

		Path to FDA approval for	ü Pathway to FDA-CVM registration in U.S with INAD file opened for THC/CBD veterinary
		Phase 2 veterinary drug	medicine for pain, Inflammation and Quality of Life in dogs; Market size of over $1B2
			ü Leveraging animal/human synergies to fast-track human programs with first exploratory
		Fast-tracking human drug
		development	study in Spinal Cord Injury in planning for early 2022; Market size of over $6B3
			ü $14m cash at bank to execute on future growth milestones, and a net asset backing of
		Well Funded for Growth
		Milestones	$0.10c; Strong upside for investors4
		APVMA (Australian, Pesticides and Veterinary Medicines Authority), FDA-CVM (Food and Drug Administration, Centre for Veterinary Medicine), INAD (Investigational New Animal Drug application), THC (tetrahydrocannabinol), CBD (Cannabidiol)
|3|	1 and 2. AusCann analysis based on Vetnosis, AnimalPharm, and other public and proprietary data sources
3. Coherent Market Insights, Spinal Cord Injury Therapeutics Market Analysis

4. As at June 30, 2021

Strategic Overview

only

Mission

Purpose

Business

Model

• To be the Australian leader in taking approved cannabinoid-based medicines to the world
• To deliver on the promise of pharmaceutically made cannabinoid-based medicine
• Immediate revenues through regulatory approved veterinary medicines and special access medical cannabis frameworks in global markets; and
• Reinvest in high-value human drug development, with significant upside for shareholders through regulatory approved human drug candidates

ersonal use

Strategic Focus

|4|

Yesterday

• Restructuring AusCann to improve cost base and refocus on high-value R&D
• Exit non-strategicloss-making operations
• Enhance R&D and pipeline through acquisition of CannPal
• Develop defensible IP through R&D and novel technologies

Today

• Progressing 1ST Australian approved veterinary medicine for immediate Revenues;
• Progressing 1ST FDA-CVM approved veterinary medicine for near term upside;
• Fast tracking high-value human drug development via internal R&D and know-how

Tomorrow

• Commencing first-in-human study in patients with Spinal Cord Injury (in design phase)
• Assessing other novel conditions for potential drug development opportunities
• Long term growth through internal product development and/or M&A opportunities

statutory expenses and operational efficiencies

activities was reduced by 45%1 in the FY21 due to reductions in

45%

reduction

The net cash used in operating

Key Milestones in 2021

March 2021

Successfully completed the acquisition of CannPal Animal Therapeutics Ltd by way of Scheme of Arrangement

only Successfully completed the

acquisition of CannPal Animal
Th rapeutics Ltd by way of
Scheme of Arrangement
use	$2.94m
	R&D
	Direct research and development
	expenses were $2,947,926, which
	accounted for 51% of the
	Company's net cash operating cash
	outflows for FY212

1.	Excluding non-cash and once off acquisition related costs
2.	Excluding non-cash and once off acquisition related costs
ersonal

1st

submission

Submitted the Company's first cannabinoid-based registration dossier for regulatory approval

$44.4m

net assets

Well-funded with net assets of $44,4m and a net cash position of $13,679,923 as of June 30, 2021

April 2021

Received clinical results for the Company's 8-week Phase 2A pilot study for FDA veterinary drug candidate, CPAT-01, confirming improvements in pain, lameness and quality of life in dogs with osteoarthritis

June 2021

Advanced the Australian product registration strategy for first-in-class veterinary medicine for skin and immune health in dogs, with receipt of an agreed registration timeline and strategy from the APVMA

September 2021

Engaged knoell Animal Health to advise on the CPAT-01 clinical Phase 2 program and U.S regulatory strategy for FDA-CVM registration

September 2021

Commenced a strategic review to support the development of new cannabinoid-based drug candidates for human registration

October 2021

Completed 90-day Target Animal Safety Study for DermaCann® in the U.S, confirming the product to be safe and well tolerated in dogs

October 2021

Submitted a pre-submission meeting conference request with the FDA- CVM for CPAT-01; meeting expected to be held in December 2021